Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Regulatory T cells (Tregs) expressing the transcription factor FoxP3 are essential for maintaining immunological balance and are a significant component of the immunosuppressive tumor microenvironment (TME). Single-cell RNA sequencing (ScRNA-seq) technology has shown that Tregs exhibit significant plasticity and functional diversity in various tumors within the TME. This results in Tregs playing a dual role in the TME, which is not always centered around supporting tumor progression as typically believed. Abundant data confirms the anti-tumor activities of Tregs and their correlation with enhanced patient prognosis in specific types of malignancies. In this review, we summarize the potential anti-tumor actions of Tregs, including suppressing tumor-promoting inflammatory responses and boosting anti-tumor immunity. In addition, this study outlines the spatial and temporal variations in Tregs function to emphasize that their predictive significance in malignancies may change. It is essential to comprehend the functional diversity and potential anti-tumor effects of Tregs to improve tumor therapy strategies.
Top-30
Journals
|
1
2
3
4
5
|
|
|
Frontiers in Immunology
5 publications, 8.47%
|
|
|
International Journal of Molecular Sciences
4 publications, 6.78%
|
|
|
Journal of Translational Medicine
3 publications, 5.08%
|
|
|
Frontiers in Pharmacology
2 publications, 3.39%
|
|
|
Cytokine
2 publications, 3.39%
|
|
|
Molecular Cancer
2 publications, 3.39%
|
|
|
Discover Oncology
2 publications, 3.39%
|
|
|
bioRxiv
1 publication, 1.69%
|
|
|
Gut Microbes
1 publication, 1.69%
|
|
|
Cancer Letters
1 publication, 1.69%
|
|
|
Medical Oncology
1 publication, 1.69%
|
|
|
Trends in Cancer
1 publication, 1.69%
|
|
|
Frontiers in Oncology
1 publication, 1.69%
|
|
|
Tzu Chi Medical Journal
1 publication, 1.69%
|
|
|
Biochemical and Biophysical Research Communications
1 publication, 1.69%
|
|
|
Cytokine and Growth Factor Reviews
1 publication, 1.69%
|
|
|
Biometrics
1 publication, 1.69%
|
|
|
PeerJ
1 publication, 1.69%
|
|
|
Brain and Behavior
1 publication, 1.69%
|
|
|
Cancer Science
1 publication, 1.69%
|
|
|
EBioMedicine
1 publication, 1.69%
|
|
|
Clinical and Translational Science
1 publication, 1.69%
|
|
|
Extreme Medicine
1 publication, 1.69%
|
|
|
Nature Reviews Clinical Oncology
1 publication, 1.69%
|
|
|
Advanced Composites and Hybrid Materials
1 publication, 1.69%
|
|
|
Hepatology International
1 publication, 1.69%
|
|
|
Clinical Cancer Research
1 publication, 1.69%
|
|
|
iMeta
1 publication, 1.69%
|
|
|
Materials Today Bio
1 publication, 1.69%
|
|
|
1
2
3
4
5
|
Publishers
|
2
4
6
8
10
12
14
16
|
|
|
Springer Nature
15 publications, 25.42%
|
|
|
Elsevier
14 publications, 23.73%
|
|
|
Frontiers Media S.A.
9 publications, 15.25%
|
|
|
MDPI
6 publications, 10.17%
|
|
|
Wiley
5 publications, 8.47%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 3.39%
|
|
|
Oxford University Press
2 publications, 3.39%
|
|
|
Taylor & Francis
1 publication, 1.69%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.69%
|
|
|
PeerJ
1 publication, 1.69%
|
|
|
Federal Medical Biological Agency
1 publication, 1.69%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 1.69%
|
|
|
AME Publishing Company
1 publication, 1.69%
|
|
|
2
4
6
8
10
12
14
16
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.